Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
Abstract
Manufacturers of insulin products for diabetes therapy have long sought ways to modify the absorption rate of exogenously administered insulins in an effort to better reproduce the naturally occurring pharmacokinetics of endogenous insulin secretion. Several mechanisms of protraction have been used in pursuit of a basal insulin for which a low injection frequency would provide tolerable and reproducible glucose control; these mechanisms have met with varying degrees of success.
Before the advent of recombinant DNA technology, development focused on modifications to the formulation that increased insulin self‐ass...
Source: Diabetes, Obesity and Metabolism - August 31, 2016 Category: Endocrinology Authors: Tim Heise, Chantal Mathieu Tags: REVIEW ARTICLE Source Type: research
Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes
Conclusions/interpretationThese results demonstrate that in a mouse model of type 2 diabetes, at high concentrations, basal insulin analogues and a non-metabolisable glargine analogue do not promote the progression of breast tumours. (Source: Diabetologia)
Source: Diabetologia - August 2, 2016 Category: Endocrinology Source Type: research
Allergic reactions to insulin detemir in women with gestational diabetes mellitus.
PMID: 27610430 [PubMed - in process] (Source: Australian Family Physician)
Source: Australian Family Physician - June 30, 2016 Category: Primary Care Authors: Morton A, Laurie J Tags: Aust Fam Physician Source Type: research
Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycaemia.
CONCLUSIONS: The analysis shows that treating people with type 1 diabetes who are prone to recurrent severe hypoglycaemia with an insulin analogue regimen is cost-effective compared with a human insulin regimen.
PMID: 27326862 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - June 23, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus
Commentary on: Herrera KM, Rosenn BM, Foroutan J, et al.. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes. Am J Obstet Gynecol 2015;213:426.e1–7. Context Pregestational diabetes (pre-GDM) and gestational diabetes mellitus (GDM) affect as many as 1.3% and 9.2% of pregnancies, respectively.1 2 Hyperglycaemia during pregnancy has been associated with a two to three times increased risk of congenital defects and with the rate of macrosomia and stillbirth in the fetus and preeclampsia in the mother compared with pregnancies in a non-diabetic population.3 The ris...
Source: Evidence-Based Medicine - May 22, 2016 Category: Internal Medicine Authors: Vellanki, P., Umpierrez, G. Tags: Clinical trials (epidemiology), Immunology (including allergy), Childhood nutrition, Diet, Pregnancy, Diabetes Therapeutics/Prevention Source Type: research
Clinical and cost outcomes of treatment with insulin glargine versus insulin detemir in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the kazakhstan setting
To evaluate the clinical and cost outcomes associated with insulin glargine (IGlar) compared to insulin detemir (IDet) treatment in insulin-naïve type 2 diabetes (T2DM) patients failing oral antidiabetic agents in the Kazakhstan, based on findings recently reported from the LOTUS2 clinical trial. (Source: Value in Health)
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A. Kostyuk, A. Akanov, A. Almadiyeva Source Type: research
A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects
Conclusion
The findings were consistent with those of the global trial population. IDeg + IAsp may represent an improvement on current standard treatments for Japanese patients with T1DM. (Source: Diabetology International)
Source: Diabetology International - April 4, 2016 Category: Endocrinology Source Type: research
A 1 ‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
ConclusionIn both type 1 diabetes and type 2 diabetes patients, switching from insulin glargine or insulin detemir to insulin degludec led to improvement of glycemic control with a significant reduction of hypoglycemia.
In both T1D and T2D subjects treated with BBT, switching from insulin glargine or detemir to insulin degludec led to improvement of glycemic control with a significant reduction of hypoglycemia. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - March 18, 2016 Category: Endocrinology Authors: Seiya Shimoda, Miki Sato, Taiji Sekigami, Hiroyuki Motoshima, Ryohei Yoshimura, Kazuki Fukuda, Yasuto Matsuo, Hideyuki Noda, Mina Okubo, Shinji Ichimori, Kazuo Fujisawa, Makiko Fukunaga, Eiichi Araki, Tags: Clinical Trial Source Type: research
Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
Conclusions
Carotid IMT change did not differ between 3 insulin regimens despite differences in HbA1c, weight gain and insulin doses. The trial only reached 46% of planned sample size and lack of power may therefore have affected our results.
Trial registration number
NCT00657943. (Source: BMJ Open)
Source: BMJ Open - February 25, 2016 Category: Journals (General) Authors: Lundby-Christensen, L., Vaag, A., Tarnow, L., Almdal, T. P., Lund, S. S., Wetterslev, J., Gluud, C., Boesgaard, T. W., Wiinberg, N., Perrild, H., Krarup, T., Snorgaard, O., Gade-Rasmussen, B., Thorsteinsson, B., Roder, M., Mathiesen, E. R., Jensen, T., Ve Tags: Open access, Cardiovascular medicine, Pharmacology and therapeutics, Diabetes and Endocrinology Research Source Type: research
Basal insulin initiation in primary vs. specialist care: similar glycaemic control in two different patient populations
ConclusionsPrimary care physicians and specialists achieved comparable improvements in glycaemic control following insulin initiation. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - February 24, 2016 Category: Internal Medicine Authors: D. Orozco‐Beltran, C. Pan, A. L. Svendsen, L. Færch, S. Caputo, Tags: Original Paper Source Type: research
Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies
CONCLUSIONS
The observational studies examining the risk of cancer associated with long-acting insulin analogs have important methodological shortcomings that limit the conclusions that can be drawn. Thus, uncertainty remains, particularly for breast cancer risk. (Source: Diabetes Care)
Source: Diabetes Care - February 23, 2016 Category: Endocrinology Authors: Wu, J. W.; Filion, K. B.; Azoulay, L.; Doll, M. K.; Suissa, S. Tags: Systematic Review Source Type: research
Converting U-500 regular insulin to insulin detemir and insulin lispro in a patient undergoing dietary changes in preparation for bariatric surgery.
CONCLUSION: Subcutaneous insulin therapy in a woman preparing for bariatric surgery was safely converted from U-500R to basal therapy with U-100 insulin detemir and with as-needed boluses of U-100 insulin lispro. This occurred as the patient switched from a regular diet to a low-calorie, high-protein diet.
PMID: 26896501 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - February 22, 2016 Category: Drugs & Pharmacology Authors: Nguyen KV, Weidner JA, Shaw KF, Valdez CA Tags: Am J Health Syst Pharm Source Type: research
Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
Conclusion: Long-standing therapy with insulin glargine was associated with a lower odds of having any fractures compared to NPH insulin. Further studies are required to investigate whether the lower chance is due to a reduced frequency of hypoglycemia. Keywords: type 2 diabetes, fracture risk, insulin treatment, oral antidiabetic medication, primary care (Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - February 19, 2016 Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study
Conclusions
This analysis demonstrates that insulin detemir has similar efficacy and safety profiles for patients with T2DM ≥65 years compared with <65 years when treated via an investigator-led algorithm. (Source: Drugs and Aging)
Source: Drugs and Aging - January 30, 2016 Category: Geriatrics Source Type: research
Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial
Conclusion
When both basal insulin analogs were given once daily in T2D, insulin detemir achieved similar efficacy to insulin glargine. On the other hand, there may be differences in action of the compared basal insulins. Further studies with larger patient samples are necessary to support evidence and reveal possible mechanisms. (Source: Advances in Therapy)
Source: Advances in Therapy - January 25, 2016 Category: Drugs & Pharmacology Source Type: research
